Sunvozertinib lung cancer treatment hit a milestone as AstraZeneca paid $600M upfront for Zegfrovy, the first oral pill to ...

AstraZeneca has secured exclusive global rights to Dizal's Zegfrovy (sunvozertinib) through a new licensing agreement.

AstraZeneca is licensing Zegfrovy from Dizal in a deal worth up to $1.5B, expanding its lung cancer portfolio with a marketed ...

AstraZeneca has continued its pipeline-boosting deal spree in China with a $1.5 billion agreement that gives it global rights ...

AstraZeneca inks exclusive global license agreement with Dizal Pharmaceutical for novel oral EGFR inhibitor Zegfrovy for lung cancer: Cambridge, UK Wednesday, July 15, 2026, 11:00 ...

AstraZeneca has acquired exclusive global rights to develop and commercialize Dizal Pharmaceutical’s marketed lung cancer drug Zegfrovy® (sunvozertinib), through an agreement that could generate up to ...

Nearly a decade after spinning out its Chinese research hub to form Dizal Pharmaceutical, AstraZeneca is paying up to $1.5 billion to buy a piece of the pipeline, securing exclusive global rights for ...

AstraZeneca has signed an exclusive global licence deal with China’s Dizal Pharmaceutical for Zegfrovy (sunvozertinib), a novel oral irreversible EGFR inhibitor for non-small cell lung cancer with ...

Duchenne muscular dystrophy (DMD) is a severe X-linked muscle-wasting disorder caused by mutations in the dystrophin gene that leads to progressive loss of mobility, cardiomyopathy and premature death ...

AstraZeneca has entered into an exclusive licence agreement with Dizal Pharmaceutical for Zegfrovy (sunvozertinib), a novel ...

On June 26, TD Cowen initiated its coverage of Dyne Therapeutics Inc. (NASDAQ:DYN), assigning a Buy rating to the stock.

Today, Dizal announced that it has entered into a global exclusive license agreement with AstraZeneca for Zegfrovy ...